Regeneron Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $1.20B | $895.5M | $636.1M | $338.1M | $413.7M | $750.3M | $-221.8M | $-104.5M |
| Depreciation & Amortization | $145.5M | $104.7M | $74.9M | $52.7M | $41.2M | $36.9M | $31.1M | $19.7M |
| Depreciation | $142.2M | $104.7M | $74.9M | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $507.3M | $559.9M | $459.0M | $321.8M | $215.4M | $94.2M | $56.1M | $39.9M |
| Net Cash from Operating Activities | $1.31B | $1.49B | $1.33B | $752.4M | $588.6M | $-74.6M | $-141.7M | $99.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $272.6M | $511.9M | $677.9M | $333.0M | $156.3M | $49.3M | $57.2M | $99.7M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-1.01B | $-1.05B | $-907.6M | $-420.8M | $-355.5M | $-81.1M | $128.5M | $-437.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $0 | $0 | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-24.4M | $-700.5M | $-262.8M | $-218.5M | $72.2M | $-97.6M | $384.2M | $243.3M |
| Net Change in Cash | $277.5M | $-261.4M | $160.4M | $113.1M | $305.3M | $-253.3M | $371.0M | $-94.5M |
| Free Cash Flow | $1.03B | $974.0M | $652.8M | $419.4M | $432.3M | $-124.0M | $-198.9M | $-467.0K |